<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Automated PRO-CTCAE Symptom Selection based on Prior Adverse Event Profiles - Health AI Hub</title>
    <meta name="description" content="This paper presents an automated method for selecting an optimal, minimal, yet comprehensive subset of PRO-CTCAE items for oncology clinical trials. The approac">
    <link rel="icon" type="image/svg+xml" href="../favicon.svg">
    <link rel="icon" type="image/png" sizes="32x32" href="../favicon-32x32.png">
    <link rel="icon" type="image/png" sizes="16x16" href="../favicon-16x16.png">
    <link rel="stylesheet" href="../styles.css">
</head>
<body>
    <header>
        <div class="container">
            <div class="breadcrumb">
                <a href="../index.html">‚Üê Back to all papers</a>
                <a href="../index.html" class="home-btn">üè† Home</a>
            </div>
        </div>
    </header>

    <main class="container paper-detail">
        <article>
            <h1>Automated PRO-CTCAE Symptom Selection based on Prior Adverse Event Profiles</h1>

            <div class="paper-metadata">
                <div class="meta-row">
                    <strong>arXiv ID:</strong> <a href="http://arxiv.org/abs/2512.06919v1" target="_blank">2512.06919v1</a>
                </div>
                <div class="meta-row">
                    <strong>Published:</strong> 2025-12-07
                </div>
                <div class="meta-row">
                    <strong>Authors:</strong> Francois Vandenhende, Anna Georgiou, Michalis Georgiou, Theodoros Psaras, Ellie Karekla
                </div>
                <div class="meta-row">
                    <strong>Categories:</strong> cs.CL
                </div>
                <div class="meta-row">
                    <strong>Relevance Score:</strong> 0.95 / 1.00
                </div>
            </div>

            <div class="action-buttons">
                <a href="http://arxiv.org/abs/2512.06919v1" target="_blank" class="btn btn-primary">View on arXiv</a>
                <a href="https://arxiv.org/pdf/2512.06919v1" target="_blank" class="btn btn-primary">Download PDF</a>
            </div>

            <section class="paper-section">
                <h2>Summary</h2>
                <p class="summary-text">This paper presents an automated method for selecting an optimal, minimal, yet comprehensive subset of PRO-CTCAE items for oncology clinical trials. The approach leverages historical adverse event data and MedDRA semantics, encoded within a semantic space called Safeterm, to balance comprehensive symptom coverage with minimizing patient burden and improving compliance.</p>
            </section>

            <section class="paper-section">
                <h2>Medical Relevance</h2>
                <p>This method is highly relevant for enhancing patient safety and data quality in oncology clinical trials by optimizing the collection of patient-reported outcomes, directly reducing patient burden while ensuring critical symptomatic adverse events are not overlooked.</p>
            </section>

            
            <section class="paper-section">
                <h2>AI Health Application</h2>
                <p>This paper describes an AI-driven automated method to optimize the selection of PRO-CTCAE symptoms for oncology clinical trials. It leverages Natural Language Processing (NLP) techniques to map medical terms (MedDRA Preferred Terms) into a semantic space (Safeterm) and uses spectral analysis to identify an optimal, diverse, and relevant set of symptoms. This application of AI streamlines clinical trial design, balances data collection with patient burden, and enhances the ability to capture important safety signals, directly impacting patient health and healthcare efficiency.</p>
            </section>
            

            <section class="paper-section">
                <h2>Key Points</h2>
                <ul class="key-points">
                    
                    <li>Addresses the critical challenge in oncology trials of selecting an appropriate number of PRO-CTCAE items to avoid patient burden (too many) or missing important safety signals (too few).</li>
                    
                    <li>Maps candidate PRO-CTCAE symptom terms to MedDRA Preferred Terms (PTs) and encodes them into Safeterm, a high-dimensional semantic space that captures clinical and contextual diversity.</li>
                    
                    <li>Scores each PRO item for relevance to historical adverse event PTs and combines this with incidence into a utility function.</li>
                    
                    <li>Applies spectral analysis to the combined utility and diversity matrix to identify an orthogonal set of medical concepts, thereby ensuring a balanced representation of diverse symptomatic adverse events.</li>
                    
                    <li>Symptoms are rank-ordered by importance, and a data-driven cut-off is suggested based on the explained information, ensuring comprehensiveness while maintaining minimality.</li>
                    
                    <li>The automated tool is implemented as part of the Safeterm trial-safety application and its performance is validated through simulations and real-world oncology case studies.</li>
                    
                    <li>Provides an objective, reproducible, and automated approach to streamline PRO-CTCAE design by leveraging MedDRA semantics and historical safety data.</li>
                    
                </ul>
            </section>

            <div class="two-column">
                <section class="paper-section">
                    <h2>Methodology</h2>
                    <p>The method involves several steps: 1) Mapping PRO-CTCAE symptom terms to corresponding MedDRA Preferred Terms (PTs). 2) Encoding these PTs into Safeterm, a high-dimensional semantic space that captures clinical and contextual diversity. 3) Scoring each candidate PRO item for relevance to a historical list of adverse event PTs, and combining this relevance with incidence into a utility function. 4) Applying spectral analysis to the combined utility and diversity matrix to identify an orthogonal set of medical concepts. 5) Rank-ordering symptoms by importance and suggesting a cut-off based on the explained information to achieve a minimal yet comprehensive set.</p>
                </section>

                <section class="paper-section">
                    <h2>Key Findings</h2>
                    <p>The automated approach successfully selects a minimal yet comprehensive PRO-CTCAE subset, demonstrating an objective and reproducible method. This method effectively leverages MedDRA semantics and historical safety data to balance the trade-off between comprehensive signal coverage for adverse events and minimizing patient burden during data collection.</p>
                </section>
            </div>

            <section class="paper-section">
                <h2>Clinical Impact</h2>
                <p>This tool can significantly streamline the design phase of oncology clinical trials by automating and optimizing PRO-CTCAE item selection. It promises to improve patient compliance, enhance the quality and relevance of patient-reported outcome data, facilitate the more efficient identification of crucial safety signals, and reduce unnecessary patient burden associated with lengthy questionnaires.</p>
            </section>

            
            <section class="paper-section">
                <h2>Limitations</h2>
                <p>The abstract does not explicitly state any limitations of the method or its current implementation.</p>
            </section>
            

            
            <section class="paper-section">
                <h2>Future Directions</h2>
                <p>The abstract does not explicitly state future research directions. However, potential future work could involve evaluating the tool's performance across diverse therapeutic areas beyond oncology, exploring dynamic item selection during a trial, or integrating other data types for further refinement.</p>
            </section>
            

            <section class="paper-section">
                <h2>Medical Domains</h2>
                <div class="tags">
                    
                    <span class="tag">Oncology</span>
                    
                    <span class="tag">Clinical Trials</span>
                    
                    <span class="tag">Pharmacovigilance</span>
                    
                    <span class="tag">Patient Safety</span>
                    
                    <span class="tag">Health Informatics</span>
                    
                </div>
            </section>

            <section class="paper-section">
                <h2>Keywords</h2>
                <div class="tags">
                    
                    <span class="tag tag-keyword">PRO-CTCAE</span>
                    
                    <span class="tag tag-keyword">MedDRA</span>
                    
                    <span class="tag tag-keyword">adverse events</span>
                    
                    <span class="tag tag-keyword">patient-reported outcomes</span>
                    
                    <span class="tag tag-keyword">semantic space</span>
                    
                    <span class="tag tag-keyword">spectral analysis</span>
                    
                    <span class="tag tag-keyword">oncology</span>
                    
                    <span class="tag tag-keyword">clinical trials</span>
                    
                    <span class="tag tag-keyword">Safeterm</span>
                    
                </div>
            </section>

            <section class="paper-section">
                <h2>Abstract</h2>
                <p class="abstract">The PRO-CTCAE is an NCI-developed patient-reported outcome system for capturing symptomatic adverse events in oncology trials. It comprises a large library drawn from the CTCAE vocabulary, and item selection for a given trial is typically guided by expected toxicity profiles from prior data. Selecting too many PRO-CTCAE items can burden patients and reduce compliance, while too few may miss important safety signals. We present an automated method to select a minimal yet comprehensive PRO-CTCAE subset based on historical safety data. Each candidate PRO-CTCAE symptom term is first mapped to its corresponding MedDRA Preferred Terms (PTs), which are then encoded into Safeterm, a high-dimensional semantic space capturing clinical and contextual diversity in MedDRA terminology. We score each candidate PRO item for relevance to the historical list of adverse event PTs and combine relevance and incidence into a utility function. Spectral analysis is then applied to the combined utility and diversity matrix to identify an orthogonal set of medical concepts that balances relevance and diversity. Symptoms are rank-ordered by importance, and a cut-off is suggested based on the explained information. The tool is implemented as part of the Safeterm trial-safety app. We evaluate its performance using simulations and oncology case studies in which PRO-CTCAE was employed. This automated approach can streamline PRO-CTCAE design by leveraging MedDRA semantics and historical data, providing an objective and reproducible method to balance signal coverage against patient burden.</p>
            </section>

            
            <section class="paper-section">
                <h2>Comments</h2>
                <p>13 pages, 2 figures</p>
            </section>
            

            
        </article>
    </main>

    <footer class="container">
        <p><a href="../index.html">‚Üê Back to all papers</a></p>
    </footer>
</body>
</html>